|
Video: What is a Stock Split?
|
|
Arbutus Biopharma is a clinical-stage biopharmaceutical company utilizing its virology expertise to develop therapeutics that target specific viral diseases. Co.'s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. Co.'s product pipeline consists of the following programs: GalNAc RNAi, which is a subcutaneously-delivered RNA interference therapeutic targeted to hepatocytes; Oral Capsid Inhibitor, which is a capsid inhibitor; Oral PD-L1 Inhibitor, which is an oral PD-L1 inhibitor that has the potential to reawaken patients' HBV-specific immune response; and Oral HBV RNA Destabilizer, which is is Co.'s oral HBV specific RNA destabilizer. According to our ABUS split history records, Arbutus Biopharma has had 1 split. | |
|
Arbutus Biopharma (ABUS) has 1 split in our ABUS split history database. The split for ABUS took place on November 04, 2010. This was a 1 for 5 reverse split, meaning for each 5 shares of ABUS owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 200 share position following the split.
When a company such as Arbutus Biopharma conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ABUS split history from start to finish, an original position size of 1000 shares would have turned into 200 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Arbutus Biopharma shares, starting with a $10,000 purchase of ABUS, presented on a split-history-adjusted basis factoring in the complete ABUS split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/31/2014 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$21.49 |
|
End price/share: |
$2.60 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-87.90% |
|
Average Annual Total Return: |
-19.04% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,210.48 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
11/04/2010 | 1 for 5 |
|
|